Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support

K. P. Papadopoulos, J. Ayello, S. Tugulea, D. F. Heitjan, C. Williams, R. F. Reiss, L. T. Vahdat, N. Suciu-Foca, K. H. Antman, C. S. Hesdorffer

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The use of CFU-GM and CD34+ cell enumeration for assessing harvest quality and factors affecting peripheral blood progenitor cell (PBPC) harvest and engraftment were investigated in 45 women with high-risk and metastatic breast cancer scheduled for dose-intensive cyclophosphamide, thiotepa, and carboplatin (CTCb). PBPC were mobilized with standard breast cancer regimens or cyclophosphamide (1.5 g/m2) and 5 μg/kg/day G-CSF and used together with G-CSF for hematopoietic support post-CTCb. There was a significant correlation between peripheral blood CD34+ cells/μl and harvest CD34+/kg (r = 0.73, p < 0.0001) and between harvest CFU-GM and CD34+ cells/kg (r = 0.5, p < 0.0001). CFU-GM clonogenic assays were of no clinical use beyond that of CD34+ cell enumeration, with the latter allowing for real-time decisions regarding harvesting. Multiple stepwise regression identified the number of prior chemotherapy cycles as the only significant clinical predictor of CD34+ cell yield. For 34 patients proceeding to CTCb with PBPC support, multiple stepwise regression identified as the best predictors for engraftment CFU-GM and CD34+ cells/kg for neutrophils and CFU-GM, CD34+ cells/kg, and the number of prior cycles of chemotherapy for platelets, respectively. A threshold dose of 1 × 106 CD34+ cells/kg, obtained in 87% of these heavily pretreated breast cancer patients, was adequate to ensure engraftment within 15 days. There was no significant difference in length of hospital stay or blood product use between patients receiving 1-2.5 × 106 CD34+ cells/kg and greater than 2.5 × 106 CD34+ cells/kg, although median time to engraftment of neutrophils (9 days versus 8 days, p = 0.007) and platelets (12 days versus 9 days, p = 0.006) was significantly longer. The established threshold of ≥1 × 106 CD34+ cells/kg will allow for more confident consideration of using aliquots of this threshold dose for hematopoietic support in sequential high-dose regimens inclusive of CTCb.

Original languageEnglish (US)
Pages (from-to)61-68
Number of pages8
JournalJournal of Hematotherapy and Stem Cell Research
Volume6
Issue number1
StatePublished - Feb 1 1997

Fingerprint

Blood Cells
Stem Cells
Breast Neoplasms
Granulocyte-Macrophage Progenitor Cells
Drug Therapy
Thiotepa
Cyclophosphamide
Carboplatin
Granulocyte Colony-Stimulating Factor
Length of Stay
Neutrophils
Blood Platelets
Cell Count

ASJC Scopus subject areas

  • Immunology
  • Hematology

Cite this

Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. / Papadopoulos, K. P.; Ayello, J.; Tugulea, S.; Heitjan, D. F.; Williams, C.; Reiss, R. F.; Vahdat, L. T.; Suciu-Foca, N.; Antman, K. H.; Hesdorffer, C. S.

In: Journal of Hematotherapy and Stem Cell Research, Vol. 6, No. 1, 01.02.1997, p. 61-68.

Research output: Contribution to journalArticle

Papadopoulos, K. P. ; Ayello, J. ; Tugulea, S. ; Heitjan, D. F. ; Williams, C. ; Reiss, R. F. ; Vahdat, L. T. ; Suciu-Foca, N. ; Antman, K. H. ; Hesdorffer, C. S. / Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. In: Journal of Hematotherapy and Stem Cell Research. 1997 ; Vol. 6, No. 1. pp. 61-68.
@article{c89b2d5f79c34b338d90cc2ee5a63b8f,
title = "Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support",
abstract = "The use of CFU-GM and CD34+ cell enumeration for assessing harvest quality and factors affecting peripheral blood progenitor cell (PBPC) harvest and engraftment were investigated in 45 women with high-risk and metastatic breast cancer scheduled for dose-intensive cyclophosphamide, thiotepa, and carboplatin (CTCb). PBPC were mobilized with standard breast cancer regimens or cyclophosphamide (1.5 g/m2) and 5 μg/kg/day G-CSF and used together with G-CSF for hematopoietic support post-CTCb. There was a significant correlation between peripheral blood CD34+ cells/μl and harvest CD34+/kg (r = 0.73, p < 0.0001) and between harvest CFU-GM and CD34+ cells/kg (r = 0.5, p < 0.0001). CFU-GM clonogenic assays were of no clinical use beyond that of CD34+ cell enumeration, with the latter allowing for real-time decisions regarding harvesting. Multiple stepwise regression identified the number of prior chemotherapy cycles as the only significant clinical predictor of CD34+ cell yield. For 34 patients proceeding to CTCb with PBPC support, multiple stepwise regression identified as the best predictors for engraftment CFU-GM and CD34+ cells/kg for neutrophils and CFU-GM, CD34+ cells/kg, and the number of prior cycles of chemotherapy for platelets, respectively. A threshold dose of 1 × 106 CD34+ cells/kg, obtained in 87{\%} of these heavily pretreated breast cancer patients, was adequate to ensure engraftment within 15 days. There was no significant difference in length of hospital stay or blood product use between patients receiving 1-2.5 × 106 CD34+ cells/kg and greater than 2.5 × 106 CD34+ cells/kg, although median time to engraftment of neutrophils (9 days versus 8 days, p = 0.007) and platelets (12 days versus 9 days, p = 0.006) was significantly longer. The established threshold of ≥1 × 106 CD34+ cells/kg will allow for more confident consideration of using aliquots of this threshold dose for hematopoietic support in sequential high-dose regimens inclusive of CTCb.",
author = "Papadopoulos, {K. P.} and J. Ayello and S. Tugulea and Heitjan, {D. F.} and C. Williams and Reiss, {R. F.} and Vahdat, {L. T.} and N. Suciu-Foca and Antman, {K. H.} and Hesdorffer, {C. S.}",
year = "1997",
month = "2",
day = "1",
language = "English (US)",
volume = "6",
pages = "61--68",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support

AU - Papadopoulos, K. P.

AU - Ayello, J.

AU - Tugulea, S.

AU - Heitjan, D. F.

AU - Williams, C.

AU - Reiss, R. F.

AU - Vahdat, L. T.

AU - Suciu-Foca, N.

AU - Antman, K. H.

AU - Hesdorffer, C. S.

PY - 1997/2/1

Y1 - 1997/2/1

N2 - The use of CFU-GM and CD34+ cell enumeration for assessing harvest quality and factors affecting peripheral blood progenitor cell (PBPC) harvest and engraftment were investigated in 45 women with high-risk and metastatic breast cancer scheduled for dose-intensive cyclophosphamide, thiotepa, and carboplatin (CTCb). PBPC were mobilized with standard breast cancer regimens or cyclophosphamide (1.5 g/m2) and 5 μg/kg/day G-CSF and used together with G-CSF for hematopoietic support post-CTCb. There was a significant correlation between peripheral blood CD34+ cells/μl and harvest CD34+/kg (r = 0.73, p < 0.0001) and between harvest CFU-GM and CD34+ cells/kg (r = 0.5, p < 0.0001). CFU-GM clonogenic assays were of no clinical use beyond that of CD34+ cell enumeration, with the latter allowing for real-time decisions regarding harvesting. Multiple stepwise regression identified the number of prior chemotherapy cycles as the only significant clinical predictor of CD34+ cell yield. For 34 patients proceeding to CTCb with PBPC support, multiple stepwise regression identified as the best predictors for engraftment CFU-GM and CD34+ cells/kg for neutrophils and CFU-GM, CD34+ cells/kg, and the number of prior cycles of chemotherapy for platelets, respectively. A threshold dose of 1 × 106 CD34+ cells/kg, obtained in 87% of these heavily pretreated breast cancer patients, was adequate to ensure engraftment within 15 days. There was no significant difference in length of hospital stay or blood product use between patients receiving 1-2.5 × 106 CD34+ cells/kg and greater than 2.5 × 106 CD34+ cells/kg, although median time to engraftment of neutrophils (9 days versus 8 days, p = 0.007) and platelets (12 days versus 9 days, p = 0.006) was significantly longer. The established threshold of ≥1 × 106 CD34+ cells/kg will allow for more confident consideration of using aliquots of this threshold dose for hematopoietic support in sequential high-dose regimens inclusive of CTCb.

AB - The use of CFU-GM and CD34+ cell enumeration for assessing harvest quality and factors affecting peripheral blood progenitor cell (PBPC) harvest and engraftment were investigated in 45 women with high-risk and metastatic breast cancer scheduled for dose-intensive cyclophosphamide, thiotepa, and carboplatin (CTCb). PBPC were mobilized with standard breast cancer regimens or cyclophosphamide (1.5 g/m2) and 5 μg/kg/day G-CSF and used together with G-CSF for hematopoietic support post-CTCb. There was a significant correlation between peripheral blood CD34+ cells/μl and harvest CD34+/kg (r = 0.73, p < 0.0001) and between harvest CFU-GM and CD34+ cells/kg (r = 0.5, p < 0.0001). CFU-GM clonogenic assays were of no clinical use beyond that of CD34+ cell enumeration, with the latter allowing for real-time decisions regarding harvesting. Multiple stepwise regression identified the number of prior chemotherapy cycles as the only significant clinical predictor of CD34+ cell yield. For 34 patients proceeding to CTCb with PBPC support, multiple stepwise regression identified as the best predictors for engraftment CFU-GM and CD34+ cells/kg for neutrophils and CFU-GM, CD34+ cells/kg, and the number of prior cycles of chemotherapy for platelets, respectively. A threshold dose of 1 × 106 CD34+ cells/kg, obtained in 87% of these heavily pretreated breast cancer patients, was adequate to ensure engraftment within 15 days. There was no significant difference in length of hospital stay or blood product use between patients receiving 1-2.5 × 106 CD34+ cells/kg and greater than 2.5 × 106 CD34+ cells/kg, although median time to engraftment of neutrophils (9 days versus 8 days, p = 0.007) and platelets (12 days versus 9 days, p = 0.006) was significantly longer. The established threshold of ≥1 × 106 CD34+ cells/kg will allow for more confident consideration of using aliquots of this threshold dose for hematopoietic support in sequential high-dose regimens inclusive of CTCb.

UR - http://www.scopus.com/inward/record.url?scp=0030987147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030987147&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 61

EP - 68

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 1

ER -